Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Pfizer presents new ACC inhibitors

May 24, 2012

Phase III CompleoTRT trial nearing full enrollment

May 24, 2012

Novel ROCK-II inhibitors prepared at Boehringer Ingelheim

May 24, 2012

ProINS-Tf fusion protein displays hypoglycemic activity

May 24, 2012

Repros submits revised documentation to FDA for Androxal studies

May 23, 2012

FDA approves expanded use of Levemir

May 23, 2012

Novel ER-alpha agonists patented

May 23, 2012

Unigene reports encouraging preclinical data on UGP-281

May 23, 2012

Novel AMPK activators designed by Roche

May 21, 2012

Levotofisopam proof-of-concept trial successfully completed

May 18, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...